Tumours of the head and neck region rank sixth in terms of prevalence worldwide and claim the lives of around half a million people each year. In a quarter of cases, head and neck carcinomas (HNSCC) are caused by human papillomaviruses (HPV) and cannot always be successfully treated at present. A research team led by Lorenz Kadletz-Wanke from the University Clinic for Ear, Nose and Throat Diseases at MedUni Vienna has discovered a new treatment option as part of a study. Patients with HPV-positive head and neck tumours have so far been treated with chemotherapy and radiotherapy. This standard approach affects the whole body, often causes severe side effects, and not all patients respond to it. In their search for targeted treatment options, the researchers were able to identify a protein that enables the prediction of above-average survival in patients with HPV-positive head and neck cancer and paves the way for progress in treatment. Specifically, this is the protein CBP, which regulates various cellular processes and is involved, amongst other things, in the development of cancer. As the study shows, CBP is significantly more active in HPV-induced head and neck tumours. “For patients with HPV-positive head and neck cancer, treatment with CBP inhibitors has the advantage that it acts in a targeted manner rather than affecting the whole body. Furthermore, it is better tolerated than conventional chemotherapy and radiotherapy, which would significantly improve the quality of life for those affected,” says Kadletz-Wanke, summarising the key finding of the research. Reference: Medical University of Vienna: Targeting Wnt/β-catenin signalling in HPV-positive head and neck squamous cell carcinoma. https://doi.org/10.3390/ph15030378 #cancer #head-and-neck-tumours #human-papillomavirus #HPV #oncology #CBP-inhibitors #science #medicine #medimpressions
New treatment option for head and neck tumours